Technology Bundle ID

The Use of Emetine for the Treatment of SARS-CoV-2 Infection

Linked ID
Lead Inventors
Noel Southall (NCATS)
Andreas Dulcey Gracia (NCATS)
Juan Marugan (NCATS)
Marc Ferrer-Alegre (NCATS)
Mark Henderson (NCATS)
Xin Hu (NCATS)
This technology includes the clinical use of the small compound emetine for the treatment of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues that may make it suitable for the treatment of COVID-19.
Commercial Applications
Further clinical work may establish emetine as a therapeutic for SARS-CoV-2.
Competitive Advantages
There are no current approved therapies for SARS-CoV-2 infection.

Request More Info

Licensing Contact: